Pharmaceutical industry in China

Vifor Pharma acquires Priority Review Voucher

Retrieved on: 
Monday, February 17, 2020

Vifor Pharma Group is a global speciality pharmaceuticals company.

Key Points: 
  • Vifor Pharma Group is a global speciality pharmaceuticals company.
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

AMAG Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Friday, February 14, 2020

WALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.(NASDAQ: AMAG) today announced that management will participate in the following investor conferences:

Key Points: 
  • WALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.(NASDAQ: AMAG) today announced that management will participate in the following investor conferences:
    A live audio webcast of each event will be accessible through the Investors section of the companys website at www.amagpharma.com .A replay of each webcast will be archived on the companys website for 30 days.
  • AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs.
  • The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas.
  • AMAG Pharmaceuticals is a registered trademark of AMAG Pharmaceuticals, Inc.

Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference

Retrieved on: 
Thursday, February 13, 2020

DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Tuesday, February 25, 2020 in New York, NY.

Key Points: 
  • DEER PARK, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Tuesday, February 25, 2020 in New York, NY.
  • Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products.
  • Eton is primarily focused on hospital injectable and pediatric oral liquid products.
  • The company has an additional eight products under development, including three that are under review with the FDA.

Cancer Cachexia Therapeutics Market 2019-2023 | High Prevalence and Incidence of Cancer Cachexia to Boost Growth | Technavio

Retrieved on: 
Thursday, February 13, 2020

Our cancer cachexia therapeutics market report covers the following areas:

Key Points: 
  • Our cancer cachexia therapeutics market report covers the following areas:
    This study identifies rising preference for novel therapies as one of the prime reasons driving the cancer cachexia therapeutics market growth during the next few years.
  • Cancer Cachexia Therapeutics Market 2019-2023: Vendor Analysis
    We provide a detailed analysis of around 25 vendors operating in the cancer cachexia therapeutics market, including some of the vendors such as AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the cancer cachexia therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Cancer Cachexia Therapeutics Market 2019-2023: Key Highlights
    Technavio is a leading global technology research and advisory company.

Active Pharmaceutical Ingredients Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

Retrieved on: 
Thursday, February 13, 2020

Biotech/biological APIs have witnessed constant technological evolution, owing to a shift from synthetic chemical APIs to biotech/biological APIs in the global active pharmaceutical ingredients market.

Key Points: 
  • Biotech/biological APIs have witnessed constant technological evolution, owing to a shift from synthetic chemical APIs to biotech/biological APIs in the global active pharmaceutical ingredients market.
  • The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region.In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing.
  • In Asia Pacific, Japan dominated the active pharmaceutical ingredients market, while the market in China is estimated to expand at a prominent CAGR during the forecast period.
  • The global active pharmaceutical ingredients market has been segmented as given below:
    Global Active Pharmaceutical Ingredients (API) Market, by Manufacturer
    Global Active Pharmaceutical Ingredients (API) Market, by APIs

ePharmacy Market Value to Hit US$ 155.4 Billion by 2026

Retrieved on: 
Wednesday, February 12, 2020

The USA and Canada are the strongest economies that can be the utmost important market in this region.

Key Points: 
  • The USA and Canada are the strongest economies that can be the utmost important market in this region.
  • The European region is anticipated to exhibit the second-largest share in the epharmacy market.
  • However, the existence of prominent players and rising pharmaceuticals needs, mostly baby boomers are fueling the growth of the global epharmacy market in the coming years.
  • Over the counter segment dominated the epharmacy market on the basis of drug type in the year 2018.

Global Endocrinology Drugs Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and AbbVie Inc. | Technavio

Retrieved on: 
Wednesday, February 12, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200212005490/en/
    Technavio has published a new market research report on the global endocrinology market from 2020-2024.
  • In addition, the use of biosimilars for endocrine disorders is anticipated to boost the growth of the endocrinology drugs market.
  • Major Five Endocrinology Drugs Market Companies:
    Abbott Laboratories operates its business through the following segments: Established Pharmaceuticals, Nutritionals, Diagnostics, and Cardiovascular and Neuromodulation.
  • Technavio has segmented the endocrinology drugs market based on the therapy area and region.

Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2020 Conference Call

Retrieved on: 
Wednesday, February 12, 2020

MONTREAL, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, February 19, 2020 to discuss the Companys financial results for the third quarter ended December 31, 2019, as well as the Companys corporate progress and other developments.

Key Points: 
  • MONTREAL, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, February 19, 2020 to discuss the Companys financial results for the third quarter ended December 31, 2019, as well as the Companys corporate progress and other developments.
  • The Company expects to file its financial statements along with its MD&A post market on February 18, 2020.
  • Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform.
  • Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease and pediatrics.

ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020

Retrieved on: 
Wednesday, February 12, 2020

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, after the close of the U.S. financial markets.

Key Points: 
  • ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, after the close of the U.S. financial markets.
  • ACADIAs management team will also host a conference call and webcast on February 26, 2020, at 5:00 p.m. Eastern Time to discuss financial results and operations.
  • The conference call also will be webcast live on ACADIAs website, www.acadia-pharm.com under the investors section and will be archived there until March 26, 2020.
  • ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor

Retrieved on: 
Wednesday, February 12, 2020

10,548,889, which is expected to provide exclusivity of X4s lead therapeutic candidate, mavorixafor (X4P-001), through 2038.

Key Points: 
  • 10,548,889, which is expected to provide exclusivity of X4s lead therapeutic candidate, mavorixafor (X4P-001), through 2038.
  • This new patent which covers critical compositions of matter enhances our already robust patent portfolio, further strengthening and extending the potential commercial horizon for mavorixafor, said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers.
  • Forward-looking statements include, without limitation, statements regarding the clinical development of mavorixafor and X4s exclusive rights over intellectual property.